Home » USA Broker Ratings » DexCom – Consenus Indicates Potential 3.2% Upside

DexCom – Consenus Indicates Potential 3.2% Upside

DexCom found using ticker (DXCM) now have 15 analysts in total covering the stock. The consensus rating is ‘Buy’. The target price ranges between 316 and 270 and has a mean target at 296.27. With the stocks previous close at 286.97 this would imply there is a potential upside of 3.2%. The day 50 moving average is 260.97 and the 200 moving average now moves to 204.6. The company has a market capitalisation of $26,247m. Visit the company website at: http://www.dexcom.com

DexCom, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient’s mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop a series of next-generation CGM products; and a collaboration with Companion Medical The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom was founded in 1999 and is headquartered in San Diego, California.

Join us on our new LinkedIn page

Follow us on LinkedIn